Comparative trial of clomiphene citrate/human menopausal gonadotropin and the contraceptive pill, followed by clomiphene citrate/human menopausal gonadotropin, in a gamete intrafallopian transfer program

ABSTRACT Objective To compare the effectiveness of letrozole and clomiphene citrate (CC) in patients with anovulatory infertility. Design Open, prospective, randomized, parallel group, multicentric, comparative trial. Setting Outpatient clinics of infertility centers in India. Patient(s) Fifty-five patients with anovulatory infertility were recruited. Twenty-seven patients (59 cycles) were given letrozole and twenty-eight patients (68 cycles) were given CC. Both drugs were given orally on days 3-7 of menstrual cycle. Intervention(s) Letrozole, CC, ovulation induction, vaginal micronized progesterone, IUI. Main outcome measure(s) Occurrence of ovulation, endometrial thickness and pregnancy rates. Result(s) Ovulation occurred in 77.9 % (46/59) of letrozole cycles and in 80.9 % (55/68) of CC cycles. The mean endometrial thickness on the day of human chorionic gonadotropin administration was 9 mm in letrozole group and 8.76 mm in the CC group. Pregnancy rate per cycle was 11.9 % (7/59) in the letrozole group and 8.8 % (6/68) in the CC group. Conclusion(s) Letrozole and CC have comparable effectiveness in anovulatory infertility patients. Letrozole may be an acceptable alternative to CC as an ovulation-inducing drug.

Download Full-text

Clomiphene citrate or medroxyprogesterone acetate with human menopausal gonadotropin in poor responders during In vitro fertilization/intracytoplasmic sperm injection treatments combined with embryo cryopreservation?

Reproductive and Developmental Medicine ◽

10.4103/2096-2924.268162 ◽

2019 ◽

Vol 3 (3) ◽

pp. 159

Author(s):

Lu Fang ◽

Xiu-Juan Qi ◽

Hong Zhu

Keyword(s):

In Vitro Fertilization ◽

Medroxyprogesterone Acetate ◽

Intracytoplasmic Sperm Injection ◽

Clomiphene Citrate ◽

Embryo Cryopreservation ◽

Poor Responders ◽

Human Menopausal Gonadotropin ◽

Vitro Fertilization

Download Full-text

A study for evaluation of two protocols comprising of clomiphene citrate, human menopausal gonadotropin with or without follicle stimulating hormone for ovulation induction in patients with infertility for intrauterine insemination

International Journal of Reproduction Contraception Obstetrics and Gynecology ◽

10.18203/2320-1770.ijrcog20192455 ◽

2019 ◽

Vol 8 (6) ◽

pp. 2487

Author(s):

Ashok Verma ◽

Shivani Sharma ◽

Suresh Verma ◽

Pankaj Sharma ◽

Tenzin Tsamo Tenga ◽

...

Keyword(s):

Menstrual Cycle ◽

Pregnancy Rate ◽

Ovulation Induction ◽

Endometrial Thickness ◽

Intrauterine Insemination ◽

Clomiphene Citrate ◽

Human Menopausal Gonadotropin ◽

Multiple Gestation ◽

Group A ◽

Group B

Background: To compare two protocols comprising of FSH/CC/HMG and CC/HMG for ovulation induction and IUI in women with infertility.Methods: 60 women with unexplained infertility were randomized using sequentially numbered opaque envelope method. Group A received inj FSH 150 units on day 2 of menstrual cycle and clomiphene citrate 100 mg from day 3-7, followed by injection HMG 150 units on day 9 of menstrual cycle. Group B received clomiphene citrate 100 mg from day 3-7, and HMG 150 units on day 7 and 9 of the menstrual cycle. Ovulation triggered with hCG 5000 units when dominant follicle was 18mm. Single IUI was done 36-42 hours afterwards.Results: Pregnancy occurred in 3 out of 30 women in 116 cycles Group A (with FSH) with a pregnancy rate of 10 percent, and 2.8% per cycle. In group B (without FSH) pregnancy occurred in 3 out of 30 women in 117 cycles with pregnancy rate of 10 percent, and 2.6% per cycle. The number of follicles per cycle was 1.36 and follicle size was 18.57 mm in group A. While in Group B numbers of follicles per cycle were 1.22, with average size of 18.9mm. Mean endometrial thickness was 7.7mm in Group A and 6.37 in Group B (p=.01, significant). Mild OHSS was observed in one woman in Group B. No other side effects were observed in both the groups.Conclusions: The controlled ovarian stimulation regimes used in this study are equally effective, easy to administer, require less intensive monitoring and fewer medications, with little risk of OHSS and multiple gestation.

Download Full-text